Previous work on cellular destruction induced by several clinically relevant anti-platelet IgG antibodies suggested antigen-speci®c mechanisms in the development of immune thrombocytopenia in mice. mAb directed against mouse platelet GPIba and integrin a IIb b 3 were highly pathogenic, and mediated their effects via different Fc-dependent (a IIb b 3 ) and Fcindependent (GPIba) pathways, indicating that clearance of IgG-bound platelets is only one event in the pathogenesis of murine thrombocytopenia. Here, we demonstrate that in addition to thrombocytopenia, targeting of platelet integrin a IIb b 3 results in acute systemic reaction and bleeding that is regulated by activating IgG Fc receptors (FcgR) and the inhibitory FcgRII. As shown by electron microscopy, anti-a IIb b 3 IgG mediated initial loss of a IIb b 3 integrin from platelet surfaces followed by rapid accumulation of a IIb b 3 antibody-containing immune complex (IC)-like structures in spleen and liver in vivo. In FcRg chain de®ciency, mice resisted bleeding, but not platelet destruction, while genetic ablation of FcgRII resulted in uncontrolled systemic reaction and severe hemorrhage leading to enhanced mortality. Together, these results provide evidence that IC formation and engagement of FcgR on effector cells determines the a IIb b 3 -speci®c part of the platelet pathology of the systemic reaction and bleeding in murine thrombocytopenia.
Introduction
Autoantibody-mediated cellular destruction contributes to the pathogenesis of several autoimmune diseases, and is thought to be speci®cally causal in the development of cytopenias such as autoimmune hemolytic anemia (AIHA) and immune thrombocytopenic purpura (ITP). In the vast majority of patients with severe ITP, pathogenic IgG autoantibodies directed against the platelet surface receptors a IIb b 3 integrin (GPIIbIIIa, ®brinogen receptor) and GPIb-V-IX (von Willebrand factor receptor) are found (1±3). Immune clearance of the resulting autoantibody-opsonized platelets leading to thrombocytopenia is considered as the major cause of bleeding complications in patients suffering from severe ITP (4, 5) . It is currently accepted that platelet destruction is mediated mainly by cells of the reticuloendothelial system and is Fc dependent (5) . Initial studies in rodents suggest a prominent role of activating IgG Fc receptors (FcgR) in this process (6, 7) . In humanized mouse models of FcgR, activation of the human platelet Fc receptor, hFcgRIIA (CD32), has been reported to result in thrombosis and shock (8) .
There are three classes of FcgR on leukocytes: the highaf®nity receptor, FcgRI, and the two low-af®nity receptors, FcgRII and FcgRIII (9, 10) . Both FcgRI and FcgRIII are multimeric receptors in association with the same FcRg chain required for assembly and signaling (11) . Animal studies using FcRg or FcgRIII mutant mice revealed that activating FcgR, especially FcgRIII, are involved in the initiation of immune complex (IC)-triggered in¯ammation and autoimmune disease (12±15). Most of the FcgRIII-and FcRg-triggered responses are balanced by the inhibitory FcgRII when co-expressed on the same effector cell (16±19). Moreover, the inhibitory FcgRII is modulated by IVIG in the treatment of thrombocytopenia in mice (20, 21) .
Recent studies using newly generated panels of mAb directed against various mouse platelet antigens, including a IIb b 3 , GPIba, GPIb-IX or GPV, have shown that differences in the antigenic speci®city of anti-platelet IgG antibodies can determine their pathogenic activities (22, 23) . Most of these mAb are able to mimick the effect of cytotoxic autoantibody by triggering transient or irreversible thrombocytopenia by both Fc-dependent and -independent mechanisms in vivo. Interestingly, only the anti-a IIb b 3 cluster of antibodies (JON mAb) recognizing conformational epitopes on a IIb b 3 integrin is effective to induce, in addition to platelet destruction, an acute systemic reaction that potentially causes hemorrhage and bleeding. It remains to be investigated whether FcgR can contribute to this a IIb b 3 -speci®c part of murine platelet pathology (23) . In this study, we examined the role of the various FcgR to the pathogenic effects of anti-mouse platelet a IIb b 3 mAb in normal mice as compared to IgG FcR knockout mice.
Methods

Mice
The generation of FcRg ±/± , FcgRIII ±/± and FcgRII ±/± mice derived from ES cells of 129 origin and backcrossed for more than eight generations with C57BL/6 mice has been described previously (11, 15, 16) . C57BL/6 mice were obtained from Charles River (Sulzfeld, Germany). All these mice were used at 8±12 weeks of age. Experiments were conducted in accordance to the regulations of the local authorities.
Antibodies FITC-conjugated polyclonal rabbit antibodies to human ®brinogen and rabbit anti-rat Ig were purchased from Dako (Glostrup, Denmark). Anti-mouse platelet IgG mAb of de®ned speci®cities were established by standard techniques as described previously (23, 24) . Anti-mouse integrin a IIb b 3 : JON1 (rat IgG2b) and JON3 (rat IgG1); anti-mouse GPIba: p0p4 (rat IgG2b) and p0p5 (rat IgG1). F(ab) 2 fragments were generated as described (23) . Antibodies were conjugated with 5-nm colloidal gold by standard methods.
Experimental thrombocytopenia, systemic reaction and bleeding
Ether anesthetized mice received either a single dose of 3 mg/ g of puri®ed anti-mouse platelet IgG antibodies in 200 ml sterile PBS i.v. or, alternatively, 7 Q 0.3 mg/g antibody i.p. were assayed at the indicated times for thrombocytopenia (as assessed by counting platelet numbers), for systemic reaction (as assessed by body temperature measurements with a rectal probe) and for bleeding [as assessed by levels of hematocrit (Ht)]. For determination of Ht, blood samples were collected into heparinized microhematocrit capillary tubes, centrifuged for 3 min at 12,000 r.p.m. in a microfuge and the percentage of packed erythrocytes was determined.
Platelet preparation and counting
Mice were bled under ether anesthesia from the retroorbital plexus. Blood was collected in a tube containing 10% (v/v) 7.5 U/ml heparin and platelet-rich plasma was obtained by centrifugation at 300 g for 10 min at room temperature. For determination of platelet counts, blood (20 ml) was obtained using siliconized microcapillaries and immediately diluted 1:100 in Unopette kits (Becton Dickinson, Heidelberg, Germany). The diluted blood sample was allowed to settle for 20 min in an improved Neubauer hemocytometer (Superior, Bad Mergentheim, Germany) and platelets were counted under a phase contrast microscope at Q400 magni®cation.
Flow cytometry
Heparinized whole blood was diluted 1:30 with modi®ed Tyrode's±HEPES buffer (134 mM NaCl, 0.34 mM Na 2 HPO 4 , 2.9 mM KCl, 12 mM NaHCO 3 , 20 mM HEPES, 5 mM glucose and 1 mM MgCl 2 , pH 6.6) and left for 30 min at 37°C prior to stimulation. For determination of surface a IIb b 3 levels, diluted whole blood was incubated with the¯uorophore-conjugated mAb JON8 which binds to an epitope on the receptor different from that recognized by anti-a IIb b 3 JON1, JON3 mAb used in experimental thrombocytopenia in vivo.
Electron microscopy
Tissue from spleen, liver and lung were harvested from antibody-treated male mice following cervical dislocation. Following the extraction of the organ tissue, they were immersion-®xed with 0.1 M cacodylate buffered 2% glutaraldehyde/2% paraformaldehyde for 4 h. Post-®xation was performed in 2% osmium tetroxide buffered at pH 7.3 with 0.1 M sodium cacodylate at 4°C over 2 h. Specimens were rinsed in cacodylate buffer 3 times, in 1% uranyl acetate and in 70% ethanol for 8 h. Dehydration was performed in a series of graded ethanol and specimens were then embedded in araldite. Semi-thin sections of plastic-embedded specimens were cut with a glass knife on a Reichert ultramicrotome and stained with methylene blue. Ultrathin sections (30±60 nm) were obtained with the help of a diamond knife on the microtome described above, placed on copper grids and examined with a Zeiss EM902A electron microscope (Zeiss, Oberkochen, Germany).
Results
Anti-a IIb b 3 IgG-induced systemic reaction and bleeding, but not thrombocytopenia, is mediated by activating FcgR
We previously generated panels of novel mAb recognizing various mouse platelet antigens and showed that antibodies against integrin a IIb b 3 and GPIba are by far the most pathogenic, resulting both in surface loss of antigen and clearance of platelets in mice (23) . However, we also found that the pathogenicity of anti-a IIb b 3 JON mAb is different to that induced by anti-GPIba p0p mAb by triggering a further acute systemic reaction and bleeding. As summarized in Fig. 1 , a bolus injection of 3 mg/g of puri®ed JON1 or JON3 (anti-a IIb b 3 rat mAb) induced hypothermia and signi®cant decreases in Ht levels in C57BL/6 mice, whereas no such effects were observed with any other tested anti-platelet antibodies, including anti-GPIba ( Fig. 1B and C) (23) . Moreover, we noted Fc-dependent (a IIb b 3 ) and Fc-independent (GPIba) events causing profound thrombocytopenia in anti-platelet IgG-treated mice (Fig. 1A) (23) .
As the pathogenic effects of anti-a IIb b 3 , but not anti-GPIba, mAb are Fc dependent, we determined the role of activating FcgR in platelet integrin a IIb b 3 -speci®c pathology using FcgRIII ±/± and FcRg ±/± miceÐthe latter defective in activating FcgRI and FcgRIII (11) . Anti-a IIb b 3 JON antibodies induced a profound thrombocytopenia in C57BL/6 control animals, or FcgRIII ±/± and FcRg ±/± mice, as documented by decreased platelet counts after i.v. injection ( Fig. 2A) . However, while the cytotoxic effects of the two different antibodies, JON1 (rat IgG2b) and JON3 (rat IgG1), were virtually identical in C57BL/6 wild-type mice, JON3 was less effective in both FcgRIII ±/± and FcRg ±/± mice, suggesting isotype-speci®c differences in the pathogenicity of the two antibodies. This difference became more obvious when the systemic reaction and bleeding responses to these antibodies were analyzed in the different mouse strains. As shown in Fig. 2 (B), C57BL/6 mice developed severe hypothermia within minutes upon i.v. injection of either JON1 or JON3. In contrast, in FcgRIII ±/± mice, only JON1, but not JON3, induced hypothermia, whereas FcRg ±/± mice were completely protected from JON1 and JON3-induced hypothermia. A similar picture emerged when Ht were monitored in those animals. While both JON1 and JON3 induced a marked decrease in Ht in wild-type mice, only JON1, but not JON3, had an effect in FcgRIII ±/± mice (Fig. 2C) . In FcRg ±/± mice, neither JON1 nor JON3 had a signi®cant effect on Ht. These ®ndings suggest that anti-a IIb b 3 antibodies elicit distinct pathogenic mechanisms for triggering thrombocytopenia or systemic reaction and bleeding, and only the latter depends on activating FcgR. While rat IgG1 strictly requires FcgRIII for the induction of these reactions, rat IgG2b appears to act through both, FcgRI and FcgRIII.
We have previously shown that repeated injections of low amounts of anti-a IIb b 3 antibodies still induce a marked drop in platelet counts and bleeding, but no longer hypothermia (23) . To investigate whether anti-a IIb b 3 mAb-induced thrombocytopenia is the cause of bleeding complications, C57BL/6 and FcRg ±/± mice were treated with 7 Q 0.3 mg/g JON1 within 6 h. As shown in Fig. 3(A) , such treatment resulted in severe thrombocytopenia in C57BL/6 mice and to a slightly lesser extent in FcRg ±/± mice. However, while most of the control mice developed signi®cant intestinal and s.c. bleeding, no such effects were observed in FcRg ±/± mice despite their decreased platelet counts (see also Fig. 7C ). The blood loss in C57BL/6 controls, but not in FcRg ±/± mice, was con®rmed when Ht was monitored in separate groups (Fig. 3B) . Since the cytotoxic effects of anti-a IIb b 3 mAb JON1 were slightly milder in the absence of the FcRg chain, it could not fully be excluded that the normal levels of Ht and the lack of bleeding in FcRg ±/± mice were due to the hemostatic function of the few remaining platelets. To test this possibility, FcRg ±/± mice ®rst received anti-a IIb b 3 mAb and after 6 h the remaining platelets were further depleted by injection of an anti-GPIba mAb. As expected, this treatment resulted in a complete loss of platelets for~4 days in FcRg ±/± mice (Fig. 3C) , but again the Ht levels remained virtually unchanged (Fig. 3D ).
Anti-a IIb b 3 IgG-induced loss of platelet integrin a IIb b 3 and subsequent IC formation in FcRg ±/± mice As recently suggested, the systemic reaction induced by antia IIb b 3 antibodies may be based on the formation of IC composed of a IIb b 3 and the antibody. This hypothesis was based on the observation that platelets in anti-a IIb b 3 -treated mice lost the integrin from the surface (23) . To examine a possible involvement of FcgR in this antibody-induced loss of a IIb b 3 from the platelet surface, FcRg ±/± and C57BL/6 control mice received 7 Q 0.3 mg/g anti-a IIb b 3 JON1 antibody and the circulating platelets were analyzed for the expression of a IIb b 3 integrin at different time points after injection. In both mouse strains platelets had lost~90% of their surface a IIb b 3 (Fig. 4A ) as well as surface-bound IgG (Fig. 4B ) as soon as 6 h after antibody injection and the circulating platelet population remained a IIb b 3 -negative in all mice for at least 4 days.
To study the process of a IIb b 3 loss in vivo, wild-type and FcRg ±/± mice received 3 mg/g gold (5 nm)-conjugated JON1 or control antibody i.v. and the organs were examined by electron microscopy at different time points (Fig. 5) . In wildtype mice, injection of gold-conjugated JON1 induced the formation of gold particle-containing clusters of electron dense material in the close vicinity of platelets as detected 20 min after injection. These clusters were mainly found in spleen (Fig. 5A) , liver and lungs, and showed a network-like formation of the electron-dense material. At 24 h after injection of the antibody, the gold particle-containing clusters were still found in these organs. At this time point, however, the density of the cluster network appeared higher when compared to the earlier time point (Fig. 5B) . Interestingly, the gold particlecontaining clusters were equally observed in FcRg ±/± mice, con®rming that the formation of these IC-like structures occurred independently of FcgRI and FcgRIII (not shown). In addition to the gold particle-containing clusters in the vicinity of platelets, gold particles were also found within macrophages of wild-type, but not FcRg-de®cient, mice 60 min after injection, suggesting that these immune cells had phagocytosed parts of the formed IC by FcgR-dependent mechanisms (not shown). Clustering of the gold-conjugated control antibody could not be observed in the organs of wild-type or FcRg chain-de®cient mice. These results suggest that anti-a IIb b 3 antibodies can induce the formation of large IC in mice and indicate that these IC are recognized by FcgR-bearing cells.
Anti-a IIb b 3 IgG-induced acute systemic reaction and bleeding results in enhanced mortality in FcgRII ±/± mice It is known that FcgRIII-dependent activation responses induced by the FcRg chain are counter-regulated by the inhibitory receptor FcgRII when co-expressed on the same effector cells. This balance has been established in various murine disease models, and is highlighted by the increased susceptibility of FcgRII ±/± mice to the pathogenic effects of antibodies in models of systemic anaphylaxis (25) and ICtriggered in¯ammation in several organs (17±19). To test the hypothesis that anti-a IIb b 3 antibodies trigger an IC-like response, their pathogenic effects were examined in FcgRII ±/± mice. A bolus injection of 3 mg/g of anti-a IIb b 3 mAb led to similar thrombocytopenia, but signi®cantly more severe hypothermia and increased mortality, in FcgRII ±/± mice as compared to control mice (Fig. 6 ). This ®nding demonstrates that the FcRg-triggered systemic reaction of the anti-a IIb b 3 IgG-induced pathology is counter-regulated by the inhibitory FcgRII.
To further de®ne the biological signi®cance of this regulation in the development of bleeding complications, C57BL/6 control and FcgRII ±/± mice received repeated injections of 7 Q 0.3 mg/g JON1. This treatment produced no hypothermia (not shown) and platelet counts dropped to almost zero after 6 h in both strains of mice (Fig. 7A) . Strikingly, however, FcgRII ±/± mice developed signi®cantly more severe bleeding than the C57BL/6 controls, and 75% of the mutant mice (nine out of 12) died within 4 days after the treatment from severe bleeding (Fig. 7B ) and subsequent multiorgan failure (Fig. 7C) .
Discussion
In this study, we have examined the speci®c contribution of FcgR in experimental anti-a IIb b 3 IgG-induced thrombocytopenia, systemic reaction and bleeding using knockout mice de®cient in either activating or inhibitory FcgR. Activating FcgR are considered to play an essential role in cellular destruction integral to the pathogenesis of several immune cytopenias and this has been con®rmed in a passive model of AIHA (26) where FcgR-de®cient mice resist cytotoxicity as a consequence of ineffective phagocytosis of erythrocytes due to the absence of activating FcgR on mononuclear phagocytes (7, 27, 28) . Initial studies in the (NZW Q BXSB) F 1 model of autoimmune thrombocytopenia suggested similar FcgRdependent mechanisms in the immune clearance of platelets (6, 7) . More recently, however, it has been shown that the antigenic speci®city of anti-platelet antibodies when directed against different mouse platelet antigens, including GPIba and integrin a IIb b 3 , is of critical importance, mediating their pathogenic effects through Fc-dependent (a IIb b 3 ) or Fcindependent (GPIba) mechanisms (23) . Surprisingly, we found that anti-a IIb b 3 IgG-induced thrombocytopenia, which is Fc dependent (Fig. 1) (23) , is not abolished in mice lacking the activating FcgRIII or the common FcRg chain (Fig. 2) , indicating a contribution of additional effectors like complement in this Fc-mediated process. Preliminary experiments in C3 mutant mice show that anti-a IIb b 3 IgG1 (JON3)-and IgG2b (JON1)-induced thrombocytopenia occurs independently of complement C3 activation (B. Nieswandt and J. E. Gessner, unpublished) , and this may suggest redundant roles of FcgR and complement in anti-a IIb b 3 IgG Fc-induced platelet destruction. Studies in mice lacking both activating FcgR and complement will be required to test whether complement provides an alternative pathway, as recently suggested in an antibody-dependent model of autoimmune vitiligo (29) .
While anti-platelet antibodies directed against GPIba (Fig. 1 ) or GPIb-IX, GPV, CD9 and linear epitopes on integrin b 3 (23) have mild to strong and irreversible effects on platelet counts, none of them induce signi®cant bleeding in mice. This indicates that the clearance of circulating platelets alone may not be suf®cient to account for bleeding complications. Importantly, only antibodies directed against conformational epitopes on the dominant platelet integrin, a IIb b 3 , can induce responses leading to systemic reaction and marked blood loss in mice (Fig. 1) (22,23) . FcRg chain de®ciency now reveals a role of activating FcgR in the anti-a IIb b 3 IgG Fc-induced processes of hypothermia and severe bleeding (Figs 2 and 3) . Moreover, we observe IgG isotype dependency in this model using rat IgG1 and IgG2b subclasses in mice lacking FcgRIII as compared to FcRg-de®cient mice. Consistent with previous ®ndings on mouse IgG isotypes (15, 27) , FcgRIII mutant mice display IgG subclass-speci®c protection when induced by anti-a IIb b 3 JON mAb of IgG1, but not IgG2b, isotypes (Fig. 2) . This suggests that FcgRIII, which is the principle activatory Fc receptor for mouse IgG1, is also speci®c for rat IgG1 with no role of FcgRI (30) . In contrast, rat IgG2b-induced effects are prevented in FcRg, but not FcgRIII, mutant mice, thus showing that individual FcgR interact differently with rat IgG isotypes in mediating platelet pathology (Fig. 2) . Together, these ®ndings suggest that anti-a IIb b 3 antibodies may trigger activating FcgR on immune effector cells in a way no other anti-platelet antibodies do by inducing the formation of antigen±antibody structures particularly ef®cient to be recognized by FcgR (with relative af®nities for FcgRIII: rat IgG1 > rat IgG2b and FcgRI: rat IgG2b > rat IgG1). However, it is important to stress that although we have previously shown similar pathogenic effects for a series of different anti-a IIb b 3 antibodies (23), these results cannot be directly extrapolated to all antibodies to this receptor complex.
As part of the normal cellular function, platelets can release microparticles after activation by diverse stimuli and this phenomenon has now been recognized for most eukaryotic cells (31, 32) . HIV-1-related immune thrombocytopenia has been reported to be associated with circulating IC that consist of platelet membrane fragments and anti-GPIIIa IgG antibodies (33) . Our ®nding that both FcRg chain-negative andpositive platelets have lost a IIb b 3 integrin (GPIIbIIIa) from their surfaces suggests FcRg-independent IC formation (Fig. 4) . Electron microscopic examinations using gold-conjugated anti-a IIb b 3 antibodies demonstrate the formation of IC-like structures in the vicinity of platelets, mainly in spleen, liver and lung (Fig. 5) . IC-like structures were equally found in wild-type and FcRg chain mutant mice, suggesting that activating FcgR act downstream of this process. This hypothesis is supported by the ®nding that gold clusters were present in macrophages of wild-type, but not FcRg mutant mice, which strongly IgG-induced bleeding and resulting organ failure in FcgRII ±/± mice. Representative pictures from wild-type, FcRg ±/± and FcgRII ±/± mice on day 3 after repeated injections of low amounts of JON1 mAb. Note the lack of bleeding in the FcRg ±/± mouse, whereas the blood loss in FcgRII ±/± mice was signi®cantly more severe than in the wild-type (WT) control, resulting in a pale appearance of the major organs, particularly liver and kidney. Such mice died from the marked blood loss and subsequent multi-organ failure. It is well known that IC can activate immune cells, including macrophages and mast cells, by FcgR-dependent mechanisms, thereby eliciting an acute in¯ammatory response (34, 35) . Furthermore, IC-dependent activation responses mediated by FcgRIII and the FcRg chain are regulated by the inhibitory FcgRII (17±19). A similar coupling is also found here in anti-a IIb b 3 IgG-induced hypothermia and bleeding. The genetic deletion of FcgRII results in enhanced sensitivity leading to uncontrolled acute systemic reaction and bleeding associated with profound mortality (Figs 6 and 7 ). These ®ndings demonstrate the balance between FcgRII inhibition and FcRg-triggered activation on effector cells as the major immunoregulatory event in the a IIb b 3 -speci®c pathology in mice.
Taken together, the results presented here suggest the existence of distinct pathogenic mechanisms that may determine the severity of hemorrhage in thrombocytopenia in mice. At least two different events are required for bleeding, one of which involves a IIb b 3 integrin and activating FcgR. IgG opsonization of platelets and their subsequent destruction represents the initial step in thrombocytopenia (20) . However, platelet clearance appears not strictly dependent on activating FcgR and does not necessarily lead to bleeding complications in mice. Platelet destruction results in severe bleeding when integrin a IIb b 3 is the target of the pathogenic antibody. Targeting of a IIb b 3 by anti-a IIb b 3 IgG antibodies induces the formation of IC ef®cient to trigger systemic reaction through engagement of activating FcgR on effector cells. The combination of thrombocytopenia and FcR-dependent downstream events is critical for fatal hemorrhage in mice. In accordance, a more severe systemic reaction, hemorrhage and profound mortality occurs as a consequence of changes in the balance of activating FcgR and the inhibitory FcgRII.
